References
- Rupprecht R, Papadopoulos V, Rammes G, Baghai TC, Fan J, Akula N, Groyer G, Adams D, Schumacher M. Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders. Nat Rev Drug Discov 2010;9:971-988. https://doi.org/10.1038/nrd3295
- Ching A, Kuhnast B, Damont A, Roeda D, Tavitian B, Dolle F. Current paradigm of the 18-kDa translocator protein (TSPO) as a molecular target for PET imaging in neuroinflammation and neuro degenerative diseases. Insights Imaging 2012;3:111-119. https://doi.org/10.1007/s13244-011-0128-x
- Zheng J, Boisgard R, Siquier-Pernet K, Decaudin D, Dolle F, Tavitian B. Differential expression of the 18 kDa translocator protein (TSPO) by neoplastic and inflammatory cells in mouse tumors of breast cancer. Mol Pharm 2011;8:823-832. https://doi.org/10.1021/mp100433c
- Austin CJD, Kahlert J, Kassiou M, Rendina LM, The translocator protein (TSPO): A novel target for cancer chemotherapy. Int J Biochem Cell Biol 2013;45:1212-1216. https://doi.org/10.1016/j.biocel.2013.03.004
-
Camsonne R, Crouzel C, Comar D, Maziere M, Prenant C, Sastre J, Moulin MA, Syrota A. Synthesis of N-[
$^{11}C$ ]methyl, N-(methyl-1-propyl)(chloro-2-phenyl)-1-isoquinoleinec arboxamide-3 (PK11195): a new ligand for peripheral benzodiazepine receptors. J Labelled Comp Radiopharm 1984;21:985-991. https://doi.org/10.1002/jlcr.2580211012 - Banati R, Newcombe J, Gunn R, Cagnin A, Turkheimer F, Heppner F, Price G, Wegner F, Giovannoni G, Miller D, Perkin D, Smith T, Hewson A, Bydder G, Kreutzberg G, Jones T, Cuzner M, Myers R. The peripheral benzodiazepine binding site in the brain in multiple sclerosis. Brain 2000;123:2321-2337. https://doi.org/10.1093/brain/123.11.2321
-
Chauveau F, Boutin H, Camp NV, Dolle F, Tavitian B. Nuclear imaging of Neuroinflammation: a comprehensive review of [
$^{11}C$ ]PK11195 challengers. Eur J Nucl Med Mol Imaging 2008;35:2304-2319. https://doi.org/10.1007/s00259-008-0908-9 - Owen D, Yeo A, Gunn R, Song KJ, Wadsworth G, Lewis A, Rhodes C, Pulford D, Bennacef I, Parker C, StJean P, Cardon L, Mooser V, Matthews P, Rabiner E, Rubio J. An 18-kDa Translocator Protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28. J Cerebr Blood F Met 2012;32:1-5. https://doi.org/10.1038/jcbfm.2011.147
- Perrone M, Moon BS, Park HS, Laquintana V, Jung JH, Cutrignelli A, Lopedota A, Franco M, Kim SE, Lee BC, Denora N. A novel PET imaging probe for the detection and monitoring of translocator protein 18 kDa expression in pathological disorders. Sci Rep 2016;6:20422. https://doi.org/10.1038/srep20422
- Lopalco A, Cutrignelli A, Denora N, Perrone M, Lacobazzi RM, Fanizza E, Lopedota A, Depalo N, de Candia M, Franco M, Laquintana V. Delivery of proapoptotic agents in glioma cell lines by TSPO ligand-dextran nanogels. Int J Mol Sci 2018;19:1155. https://doi.org/10.3390/ijms19041155
-
Kim GR, Paeng JC, Jung JH, Moon BS, Lopalco A, Denora N, Lee BC, Kim SE. Assessment of TSPO in a rat experimental autoimmune myocarditis model: A comparison study between [
$^{18}F$ ]fluoromethyl-PBR28 and [$^{18}F$ ]CB251. Int J Mol Sci 2018;19:276. https://doi.org/10.3390/ijms19010276 - Choi JY, Iacobazzi RM, Perrone M, Margiotta N, Cutrignelli A, Jung JH, Park DD, Moon BS, Denora N, Kim SE, Lee BC. Synthesis and evaluation of tricarbonyl 99mTc-labeled 2-(4-chloro)phenyl-imidazo[1,2-a]pyridine analogs as novel SPECT imaging radiotracer for TSPOrich cancer. Int J Mol Sci 2016;17:1085. https://doi.org/10.3390/ijms17071085
-
Choi JY, Jung JH, Song IH, Moon BS, Lee BC, Kim SE. Synthesis and biological evaluation of tricarbonyl technetium labeled 2-(4-chloro)phenyl-imidazo[1,2-a] pyridine analog (
$^{99m}Tc$ -CB257) as a TSPO-binding ligand. J Radioparm Mol Probes 2018;4:73-79. - Denora N, Lee C, Lacobazzi RM, Choi JY, Song IH, Yoo JS, Piao Y, Lopalco A, Leonetti F, Lee BC, Kim SE. TSPO-targeted NIR-fluorescent ultra-small iron oxide nanoparticles for glioblastoma imaging. Eur J Pharm Sci 2019;139:105047. https://doi.org/10.1016/j.ejps.2019.105047
- Torchilin V. Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery. Nat. Rev. Drug. Discov. 2014;13:813-827. https://doi.org/10.1038/nrd4333
- Shi J, Kantoff PW, Wooster R, Farokhzad OC. Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer 2017;17:20-37. https://doi.org/10.1038/nrc.2016.108
- Trapani G, Franco M, Latrofa A, Ricciardi L, Carotti A, Serra M, Sanna E, Biggio G, Liso G. Novel 2-phenylimidazo[1,2-a]pyridine derivatives as potent and selective ligands for peripheral benzodiazepine receptors: synthesis, binding affinity, and in vivo studies. J Med Chem 1999;42:3934-3941. https://doi.org/10.1021/jm991035g
- Denora N, Laquintana V, Pisu M, Dore R, Murru L, Latrofa A, Trapani G, Sanna E. 2-Phenyl-imidazo[1,2-a]pyridine compounds containing hydrophilic groups as potent and selective ligands for peripheral benzodiazepine receptors: synthesis, binding affinity and electrophysiological studies. J Med Chem 2008;51:6876-6888. https://doi.org/10.1021/jm8006728